# RALLYBIO CORPORATION (RLYB) · Edgar & Edgarette company card

> Rallybio (RLYB) grew revenue 34.9% in FY2025 to $1 million, operating margin -3854% against a -3.8% median for pharmaceutical preparations, equity 93.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1739410 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/RLYB) · [JSON](https://www.pops4.com/boards/company/RLYB.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $858,000 |
| Revenue growth, 1 year | 34.9% |
| Revenue growth per year | — |
| Operating margin | -3853.6% (prior year -9511.9%) |
| Net margin | -1046.4% |
| Operating cash flow | −$30M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $31M |
| Long-term debt | — |
| Total assets | $62M |
| Total equity | $58M |
| Equity ÷ assets | 93.1% |
| Return on equity | -15.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 0.76 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$29.8M in FY2025); operating loss: a margin of -3853.6% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $858K (FY2025). Experience: revenue up 34.9% on the year; operating margin -3853.6%, up from -9511.9%. Soundness: equity 93.1% of assets, return on equity -15.5%. Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $849K and $1.5M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -3853.6% against a -3.8% median; growth 34.9% against 13.7%.

Range logged 2026-10-09, receipt 12e6ba71e3e93bd7, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 5, latest 2026-11-04 ([filing](https://www.sec.gov/Archives/edgar/data/1739410/000119312526447550/0001193125-26-447550-index.htm))

## Recent filings

- 8-K · filed 2026-11-12 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1739410/000119312526458624/0001193125-26-458624-index.htm)
- 8-K · filed 2026-11-10 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1739410/000119312526455762/0001193125-26-455762-index.htm)
- 8-K · filed 2026-11-06 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1739410/000119312526452115/0001193125-26-452115-index.htm)
- 8-K · filed 2026-11-04 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1739410/000119312526447550/0001193125-26-447550-index.htm)
- 10-Q · filed 2026-10-27 · [filing](https://www.sec.gov/Archives/edgar/data/1739410/000162828026067422/0001628280-26-067422-index.htm)
- 8-K · filed 2026-10-26 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1739410/000119312526432114/0001193125-26-432114-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001739410.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1739410

## Cite

POPS4, Edgar & Edgarette: RALLYBIO CORPORATION (RLYB) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/RLYB. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

